These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18989118)

  • 1. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
    Omuro AM; Delattre JY
    Curr Opin Neurol; 2008 Dec; 21(6):717-9. PubMed ID: 18989118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
    J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
    Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A
    Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
    de Groot JF; Yung WK
    Cancer J; 2008; 14(5):279-85. PubMed ID: 18836331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
    Buie LW; Valgus J
    Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.
    Zhang W; Qiu XG; Chen BS; Li SW; Cui Y; Ren H; Jiang T
    Chin Med J (Engl); 2009 Jun; 122(11):1250-4. PubMed ID: 19567132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
    Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
    Ali SA; McHayleh WM; Ahmad A; Sehgal R; Braffet M; Rahman M; Bejjani G; Friedland DM
    J Neurosurg; 2008 Aug; 109(2):268-72. PubMed ID: 18671639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avastin: more questions than answers. .
    Desjardins A; Sampson JH
    J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
    [No Abstract]   [Full Text] [Related]  

  • 10. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
    Vredenburgh JJ; Desjardins A; Reardon DA; Peters KB; Herndon JE; Marcello J; Kirkpatrick JP; Sampson JH; Bailey L; Threatt S; Friedman AH; Bigner DD; Friedman HS
    Clin Cancer Res; 2011 Jun; 17(12):4119-24. PubMed ID: 21531816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
    Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
    Tabouret E; Barrie M; Thiebaut A; Matta M; Boucard C; Autran D; Loundou A; Chinot O
    J Neurooncol; 2013 Sep; 114(2):191-8. PubMed ID: 23756726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
    Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
    Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
    Jakobsen JN; Hasselbalch B; Stockhausen MT; Lassen U; Poulsen HS
    Expert Opin Pharmacother; 2011 Apr; 12(5):825-33. PubMed ID: 21385110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
    Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B
    Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
    Kang TY; Jin T; Elinzano H; Peereboom D
    J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase I inhibitors for the treatment of brain tumors.
    Feun L; Savaraj N
    Expert Rev Anticancer Ther; 2008 May; 8(5):707-16. PubMed ID: 18471044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
    Zustovich F; Lombardi G; Pastorelli D; Farina P; Furini L; Manara R; Dalla Palma M; Rotilio A; Nicoletto O; Zagonel V
    Anticancer Res; 2010 Dec; 30(12):5213-6. PubMed ID: 21187515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.
    Paldino MJ; Desjardins A; Friedman HS; Vredenburgh JJ; Barboriak DP
    Br J Radiol; 2012 Apr; 85(1012):382-9. PubMed ID: 21224297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.